2019 American Society of Hematology Annual Meeting *

December 7-10, 2019; Orlando, Florida
Review slidesets and analyses of key data from the 2019 Hematology meeting.

Share

Program Content

Activities

Key Studies: ASH 2019
Preview of ASH 2019: Key Expert-Selected Studies
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2019

Expires: December 04, 2020

ASH 2019 Highlights
New Insights in Hematologic Malignancies and Disorders: Independent Conference Coverage of the 2019 ASH Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2020

Expires: March 16, 2021

10 Capsule Summary Slidesets

Activities

E2906: DAC Maintenance
ECOG-ACRIN E2906: Maintenance Decitabine After Response to Intensive Therapy in Older AML Patients
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

TDT and Prognosis in AML
Analysis: Prognostic Effect of Time From Diagnosis to Treatment in Newly Diagnosed AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

FLAG-IDA plus Venetoclax in AML
Phase Ib/II Study: FLAG-IDA Plus Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

Frontline Ponatinib in ALL
First-line Hyper-CVAD Plus Ponatinib in Adults With Ph+ Acute Lymphoblastic Leukemia: Long-term Safety and Efficacy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2019

Expires: December 08, 2020

Venetoclax + Navitoclax in ALL/LL
Results From Phase I M16-106 Study of Venetoclax Plus Navitoclax in Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2019

Expires: December 07, 2020

ENA + AZA in ND mIDH2 AML
Interim Phase II Results From AG221-AML-005: Enasidenib + Azacitidine vs Azacitidine Alone in Newly Diagnosed AML With IDH2 Mutations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

R/R AML After VEN + HMA
Outcomes in R/R AML After First-line Treatment With Venetoclax Plus a Hypomethylating Agent
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

Ph+ ALL: Dasatinib + Blinatumomab
Updated Analysis of Frontline Dasatinib + Blinatumomab in Patients With Newly Diagnosed Ph+ ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2019

Expires: December 16, 2020

Blinatumomab in B-ALL
Phase III Trial of Blinatumomab vs Chemotherapy as Post-Reinduction Therapy for Children and Young Adults With Relapsed B-ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

QUAZAR AML-001
QUAZAR AML-001: Phase III Study of CC-486 Maintenance Therapy in Patients With Acute Myeloid Leukemia in First Remission
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

Activities

ASH 2019: Leukemias
Leukemias: Key Trials From ASH 2019
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: February 03, 2020

Expires: February 01, 2021

11 Capsule Summary Slidesets

Activities

TRANSCEND NHL 001
TRANSCEND NHL 001: Phase I Study of Lisocabtagene Maraleucel in R/R LBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2019

ELEVATE TN
ELEVATE TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2019

Expires: December 09, 2020

Frontline AVO in CLL
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab Combination Therapy in Previously Untreated CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2019

Expires: December 07, 2020

VEN+IBR in High-Risk CLL
Venetoclax and Ibrutinib Combination Therapy for Treatment-Naive High-Risk CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

Phase II CAPTIVATE Study
Phase II CAPTIVATE Trial of First-line Ibrutinib Plus Venetoclax in CLL/SLL: MRD Cohort Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2019

Expires: December 09, 2020

LOXO-305 in CLL/B-Cell NHL
BRUIN: First-in-Human Phase I Trial Investigating Non-Covalent BTK Inhibitor LOXO-305 in Pretreated B-Cell Malignancies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

TRANSCEND CLL 004 Updates
Phase I/II TRANSCEND CLL 004: Updated Results of Lisocabtagene Maraleucel in Patients With Relapsed/Refractory CLL or SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

Mosunetuzumab in R/R NHL
Phase I/Ib Study of Mosunetuzumab in Heavily Pretreated Patients With R/R B-Cell Non-Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2019

Expires: December 10, 2020

TRANSCEND NHL 001: PROs With Liso-Cel
TRANSCEND NHL 001: Patient-Reported Outcomes With Liso-Cel in Patients With Relapsed/Refractory Aggressive B-Cell NHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

KTE-X19 in R/R MCL
Phase II ZUMA-2 Trial of KTE-X19 CAR T-Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

Real-world Axi-Cel Data
Postmarketing Outcomes of CD19-Directed CAR T-Cell Agent Axicabtagene Ciloleucel for Treatment of Large B-Cell Lymphoma in the United States
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

Activities

ASH 2019: CLL/Lymphomas
My Take on Key Studies in CLL and Lymphomas From ASH 2019
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: January 23, 2020

Expires: January 21, 2021

5 Capsule Summary Slidesets

Activities

VEN ± AZA in MDS
Phase Ib Study: Venetoclax With or Without Azacitidine for Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
Luspatercept for Anemia in MF
Phase II Study: Luspatercept for Treatment of Myelofibrosis-Associated Anemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2019

Expires: December 06, 2020

APR-246 + AZA in MDS/AML
Phase Ib/II Trial of APR-246 + Azacitidine in TP53-Mutant MDS and AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

TP53 Mutant MDS/AML: APR-246 + Aza
GFM Phase II Study of APR-246 Plus Azacitidine in TP53-Mutated MDS and AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

MEDALIST: Luspatercept in MDS
Updated Analysis From the Phase III MEDALIST Trial of Luspatercept to Treat Anemia in Lower-Risk RBC Transfusion-Dependent MDS With Ring Sideroblasts
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

Activities

ASH 2019: MPN/MDS
Advances in MDS and MPN From ASH 2019
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: March 09, 2020

Expires: March 08, 2021

15 Capsule Summary Slidesets

Activities

GEM-CLARIDEX: Rd ± Clarithromycin
Phase III GEM-CLARIDEX: Clarithromycin Plus Rd vs Rd Alone in Newly Diagnosed, Transplant-Ineligible Patients with Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
STOMP: Selinexor + Pd
Phase I/II STOMP Trial: Selinexor, Pomalidomide, and Dexamethasone in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

CC-93269 in MM
First Clinical Study of CC-93269, a BCMA 2+1 T-Cell Engager, in Relapsed/Refractory Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2019

Expires: December 08, 2020

Phase Ib/II CARTITUDE-1
Phase Ib/II CARTITUDE-1 Study of BCMA-Directed CAR T-Cell Therapy JNJ-4528 in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

LEGEND-2: LCAR-B38M in R/R MM
LEGEND-2 Long-term Follow-up: Phase I Trial of LCAR-B38M CAR T-Cell Therapy in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

CASSIOPET: PET/CT in MM
CASSIOPET: CASSIOPEIA Companion Study Evaluating Prognostic Value of PET/CT in Newly Diagnosed, Transplant-Eligible Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

HOVON 143: IxaDaraDex in ND MM
Phase II HOVON 143 Trial: Interim Analysis of Ixazomib/Daratumumab/Low-Dose Dex in Unfit, Frail Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

GEM-CESAR: KRd in SMM
Phase II GEM-CESAR: Carfilzomib/Lenalidomide/Dexamethasone as Curative Regimen for High-Risk Smoldering Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

ALCYONE 3-Yr Follow-Up
ALCYONE 3-Yr Follow-up: Daratumumab Plus VMP vs VMP Alone in Newly Diagnosed, Transplantation-Ineligible Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

MASTER: Dara-KRd in NDMM
MASTER Trial: Response-Adapted Dara-KRd Sequential Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2019

Expires: December 08, 2020

Daratumumab + IRd With Dose-Modified Dex in NDMM
Phase II Trial of Daratumumab Plus Ixazomib/Lenalidomide/Dose-Modified Dexamethasone in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2019

Expires: December 16, 2020

Venetoclax + Dex in R/R MM
Phase I/II Study of Venetoclax + Dexamethasone in Patients With t(11;14) R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

CANDOR: KdD in R/R MM
Phase III CANDOR Trial of Carfilzomib, Dexamethasone ± Daratumumab in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

Venetoclax/Dara/Dex ± Bortezomib in R/R MM
Venetoclax/Daratumumab/Dexamethasone ± Bortezomib in Patients With R/R MM: Initial Analysis of a Phase I/II Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
GRIFFIN: VRd ± Dara
GRIFFIN Update: Phase II Study of Daratumumab + VRd vs VRd Alone for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Activities

ASH 2019: Myeloma
My Thoughts on Key Studies in Myeloma From ASH 2019
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2020

Expires: February 24, 2021

7 Capsule Summary Slidesets

Activities

Avatrombopag In ITP
Updated Results From a Randomized Phase III Trial of Avatrombopag in Patients With Chronic ITP
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2019

Expires: December 09, 2020

BELIEVE Subanalysis
BELIEVE Subanalysis: Evaluation of Responders With Transfusion-Dependent β-Thalassemia to Luspatercept
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

Northstar-3 (HGB-212)
Interim Results From the Phase III Northstar-3 (HGB-212) Study of Betibeglogene Autotemcel in Patients With Severe Transfusion-Dependent β-Thalassemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

PRN1008 in ITP
Phase I/II Evaluation of Novel BTKi PRN1008 in R/R Primary or Secondary Immune Thrombocytopenia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2019

Expires: December 08, 2020

Sutimlimab in Chronic ITP
Phase I Trial of Sutimlimab to Inhibit Classical Complement Pathway in Patients With Multi-Refractory Chronic Immune Thrombocytopenia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2019

Expires: December 16, 2020

CARDINAL: Sutimlimab for CAD
CARDINAL: Phase III Study of Sutimlimab in Patients With Cold Agglutinin Disease and a Recent History of Transfusion
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

SCD: <i>BCL11A</i> Gene Therapy
Pilot Feasibility Study of BCL11A as Gene Therapy Target in Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

Activities

Nonmalignant Heme Commentary
Nonmalignant Hematologic Disorders: Key Trials From ASH 2019
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 18, 2020

Expires: February 16, 2021

Faculty

cover img faculity

Hanny Al-Samkari, MD

Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

cover img faculity

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

cover img faculity

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

cover img faculity

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.